The Effect of Handmade Del Nido Cardioplegia Solution with Handmade St. Thomas Cardioplegia Solution in terms of Quantitative Levels of Cardiac Troponin I and Phosphocreatine kinase MB.
Phase 2
Recruiting
- Conditions
- Ventricular Septal Defect Repair.Ventricular septal defect as current complication following acute myocardial infarction
- Registration Number
- IRCT20171230038142N8
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Having less than 12 years of age.
Parental satisfaction from intervention.
Exclusion Criteria
Having a history of heart failure.
Having a history of myocardial infarction.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantitative Levels of Cardiac Troponin I. Timepoint: Before surgery, six hours and 12 hours after surgery. Method of measurement: Patient blood sample test.;Quantitative Levels of Phosphocreatine kinase MB. Timepoint: Before surgery, six hours and 12 hours after surgery. Method of measurement: Patient blood sample test.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie myocardial protection differences between Del Nido and St. Thomas cardioplegia solutions in pediatric VSD repair?
How does handmade Del Nido cardioplegia compare to St. Thomas solution in reducing postoperative cardiac troponin I elevation in pediatric cardiac surgery?
Which biomarkers correlate with improved outcomes in IRCT20171230038142N8 pediatric VSD repair trials using cardioplegia solutions?
What are the potential adverse events associated with handmade cardioplegia solutions in pediatric patients with ventricular septal defects?
How do adjuvant agents in Del Nido and St. Thomas cardioplegia solutions influence phosphocreatine kinase MB levels post-VSD repair?